SAN DIEGO, CA – February 2, 2015 – Viking Therapeutics, Inc., a clinical-stage company focused on developing novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced that it has entered into a research collaboration agreement with the Academic Medical Center (AMC) of ...Read the rest

Ligand to invest $2.5 million to support development of novel treatments for diabetes, cancer cachexia, dyslipidemia and anemia    Print PDF SAN DIEGO, CA, May 22, 2014 – Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies ...Read the rest

Press Release  Print PDF New York, March 7, 2014 – (BUSINESS WIRE) – Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper ...Read the rest